Compare Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Russell 2000 0DTE Covered Call Strat ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $25.29 (market cap $159.50M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 30.6× Roundhill Russell 2000 0DTE Covered Call Strat ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Roundhill Russell 2000 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Russell 2000 0DTE Covered Call Strat ETF for 56 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| RDTE | TVTX | |
|---|---|---|
Market Cap | $159.50M | $4.88B |
Volume | 55,754 | 1,668,577 |
Sector | Income / Options Overlay | Health |
52-Week High | $33.66 | $67.52 |
52-Week Low | $25.43 | $26.79 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RDTE (Roundhill Russell 2000 0DTE Covered Call Strategy ETF) trades at $25.91, down 0.54% with bearish technical indicators showing 17 sell signals versus 0 buy signals. The ETF faces capital erosion concerns despite offering high dividend yields through its covered call strategy on Russell 2000 small-cap stocks. Recent dividend payments have ranged from $0.10 to $0.23 per share, but the fund's income generation comes with significant price depreciation risk.
The outlook remains challenging as technical analysis indicates strong bearish momentum with moving averages unanimously signaling sell. Fundamental data is limited but the covered call strategy exposes investors to capped upside potential during market rallies while providing limited downside protection. Key risks include small-cap volatility and the structural limitations of 0DTE options strategies in generating sustainable income.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
